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Background: Data on the effect of oral bisphosphonates (BPs) on risk of upper gastrointestinal complications (UGIC)
are conflicting. We conducted a large population-based study from a network of Italian healthcare utilization databases
aimed to assess the UGIC risk associated with use of BPs in the setting of secondary prevention of osteoporotic fractures.
Methods: A nested case–control study was carried out within a cohort of 68,970 patients aged 45 years or older, who
have been hospitalized for osteoporotic fracture from 2003 until 2005. Cases were the 804 patients who experienced
hospitalization for UGIC until 2007. Up to 20 controls were randomly selected for each case. Conditional logistic
regression model was used to estimate odds ratio (OR) associated with current and past use of BPs (i.e. for drug
dispensation within 30 days and over 31 days prior the outcome onset, respectively) after adjusting for several covariates.
Results: Compared with patients who did not use BPs, current and past users had OR (and 95% confidence interval) of
0.86 (0.60 to 1.22) and 1.07 (0.80 to 1.44) respectively. There was no difference in the ORs estimated according with BPs
type (alendronate or risedronate) and regimen (daily or weekly), nor with co-therapies and comorbidities.
Conclusions: Further evidence that BPs dispensed for secondary prevention of osteoporotic fractures are not associated
with increased risk of severe gastrointestinal complications is supplied from this study. Further research is required to
clarify the role BPs and other drugs of co-medication in inducing UGIC.
Keywords: Bisphosphonates, Drug safety, Healthcare utilization database, Upper gastrointestinal complicationsBackground
Osteoporotic fractures are becoming a major cause of mor-
bidity and mortality worldwide. The lifetime risk of typical
osteoporotic fracture (i.e., of the wrist, hip, or vertebra) has
been reported to be around 40% [1-3]. Ideally, osteoporosis
should be prevented before fragility fractures occur.
Nevertheless, an important clinical strategy is to identify
patients who have already had a typical osteoporotic
fracture and institute treatments aimed at secondary
prevention [4-7]. In postmenopausal women, at least 80%
to 90% of fractures of the wrist, hip, or vertebra are* Correspondence: giovanni.corrao@unimib.it
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reproduction in any medium, provided the orassociated with osteoporosis [8-10] and an osteoporotic
patient who experience a fracture has approximately a
20-fold risk of future fracture compared with a patient who
has neither osteoporosis nor a history of fracture [2,11].
Oral bisphosphonates (BPs), such as alendronate and
risedronate, are considered the mainstay therapy for the
prevention of osteoporotic fractures. Randomised clin-
ical trials (RCTs) have consistently shown that long-term
treatment with these medicaments improves bone mineral
density (BMD) and reduces the risk of fracture [12-19].
However, long-term therapy is required to increase and
maintain BMD and to keep normal levels of bone resorp-
tion [20]. Therefore, therapy must be generally safe, besides
being effective, in a long-term fashion.
Data from the pivotal RCTs of both alendronate
[12-14,19] and risedronate [16-18,20,21] did not foundl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing that these drugs are well tolerated. However, soon
after alendronate release, an unexpected higher number
of cases of oesophagitis and oesophageal strictures were
encountered when the drug was prescribed to the general
population, which resulted in changes to the alendronate
label [22,23]. From then on nowadays, inconsistent find-
ings on gastrointestinal (GI) safety of BPs have been
reported [24-29]. Two meta-analyses on this topic came
to conflicting conclusions [30,31], suggesting that evi-
dence on gastrointestinal safety of these agents are still
insufficient.
To shed further light on the association between use
of BPs and the risk of hospitalization for upper gastro-
intestinal complications (UGIC), we carried out a large
nested case–control study in a cohort of patients hospi-
talized for osteoporotic fracture.
Methods
Data source
The data used for the present study were retrieved from
the health service databases of all the 13 Italian territorial
units participating at the AIFA-BEST (Bisphosphonates
Effectiveness-Safety Tradeoff) project. The general aim of
this project is to provide an assessment of the benefit-risk
profile of BPs use. Further details of the study design and
procedure can be found elsewhere [32].
Territorial units participant to the AIFA-BEST project
were four Regions (Abruzzo, Emilia-Romagna, Marche
and Toscana) and nine Local Health Authorities (Caserta,
Como, Gorizia, Latina, Lodi, Milano, Monza, Sondrio and
Varese). A population of about 17 million of beneficiaries
of National Health Service (NHS) residents in these terri-
torial units was covered by the corresponding HCU data-
bases, accounting for nearly 30% of the whole Italian
population.
Italian population is entirely covered by the NHS
that provides universal and free of charge coverage
for many healthcares, such as hospitalizations for any
causes and several drug therapies (including medica-
ments for treatment of osteoporosis). This program is
administered by an automated system of databases on
the use of health services supplied free of charge from
NHS and including: (i) an archive of beneficiaries of
NHS (practically the whole resident population), inclu-
sive of demographic and administrative data; (ii) details
of hospitalizations in private and public hospitals, inclu-
sive of diagnosis at discharge; and (iii) outpatients
medicament prescriptions reimbursable from the NHS
[according to Italian rules, outpatients medicaments
supplied free of charge from NHS may be dispensed
only from pharmacies and only by prescription]. With
the aim of obtaining the complete history of health-
care utilization of all the NHS beneficiaries, the differentpieces of information recorded into these databases can
be linked using a unique personal identification code.
In order to preserve privacy, we replaced the original
identification code with its digest that is the image of
the code through a cryptographic hash function – the
Secure Hash Algorithm (SHA-256). Such hash function
(i) makes infeasible to obtain the original code from the
digest, (ii) is deterministic, i.e. the same digest is always
associated to any given individual, and (iii) is collision-
resistant, i.e. the probability that two individuals are as-
sociated to the same code is insignificant. The specific
hash function used (SHA-256) is the industry standard
[33] and has been incorporated into the data extraction-
transformation-load software produced by the University
of Milano-Bicocca.
Data were drawn out from databases by means of stan-
dardized queries which were defined and tested ac-
cording to the study protocol. Additional file 1 provides
specific diagnostic and therapeutic codes used for our
study.
Cohort selection
We identified patients aged 45 years or older who have
been hospitalized for osteoporotic fracture from July 1,
2003 until December 31, 2005 and the date of hospital
discharge was designed as that of entry into the cohort.
Patients were excluded if, within six months prior the
cohort entry date, they had at least one BPs prescription
or they have been hospitalized for bone fracture, gastro-
intestinal adverse events, Paget’s disease, coagulation dis-
orders, alcohol abuse, chronic liver disease or cancer.
Patients who were registered into the archive of NHS
beneficiaries from less than six months prior the entry
into the cohort and those who did not reach at least
60 days of follow-up were also excluded. The remaining
patients constituted the study cohort.
Each member of the cohort accumulated person-
years of follow-up from the date of entry until the
earliest date among those of outcome onset (hospital
admission for UGIC) or censoring (death, emigration or
31 December 2007).
Selection of cases and controls
We identified patients who during follow-up experi-
enced at least a hospitalization with diagnosis of UGIC
including oesophageal/gastrointestinal ulcer, perforation
of oesophagus, oesophageal/gastrointestinal haemorrhage
(see Additional file 1: Table S1). A patient who experienced
at least one of these events was considered as having the
outcome. The earliest date of hospital admission recording
one of these events was considered as the index date.
Up to twenty controls for each case patient were se-
lected randomly from the cohort to be matched for ter-
ritorial unit of recruitment, gender, age at cohort entry,
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outcome at the time when the matched case had the
event. In these conditions each set established from one
case and the corresponding matched controls had the
same extension of observational period which began at
the date of index prescription and stopped at the event
date of the index case.
Exposure assessment
During the study period two drug types (alendronate
and risedronate) either on once-daily (10 mg/day and
5 mg/day, respectively) or once-weekly (70 mg/week and
35 mg/week, respectively) regimens were available for
free reimbursement by Italian NHS.
Drug-dispensing history of BPs prescribed to cases and
controls during the observational period was assessed
from the prescription drug database. Exposure was cate-
gorized into mutually exclusive groups of current, past,
and no use, taking as reference the index date [27]. A pa-
tient was defined current user if at least one prescription
of BPs was dispensed within 30 days or less prior the
index date. Past users were defined as those who at least
one prescription of BPs was dispensed later than 31 days
prior the index date. No users were patients who during
the entire observational period did not experience BPs
dispensation.
Covariates
For each case and control the dispensation of some me-
dicaments over the 60-day period prior the index date
was investigated. Medicaments included antidepressants,
antithrombotic, gastroprotective agents, corticosteroids,
statins, calcium channel blockers, other antihypertensive
agents and nonsteroidal antiinflammatory agents (NSAIDs)
(see Additional file 1: Table S1). In addition, the Charlson
comorbidity index score was calculated [34], using the
diagnostic information available from inpatient charts in
the six months prior the date of entry into the cohort and
during the entire period of follow-up. Two categories of
the Charlson comorbidity index score were considered, i.e.
0 and 1, respectively denoting absence and presence of at
least one comorbidity.
Statistical analyses
Chi-square was used to test differences between cases
and controls. A conditional logistic regression model
was fitted to estimate the odds ratio (OR), as well as its
95% confidence interval (CI), of UGIC associated with
use of BPs (anytime, current or past), taking non-use as
reference. Adjustments were made for the above re-
ported covariates. The combined effect of BPs with co-
treatments and co-morbidity was estimated by including
the corresponding interaction terms in a conditional lo-
gistic model. The differential effect of type and regimenof the dispensed BPs was also evaluated by means of
stratification analysis.
Sensitivity analyses
The following sets of sensitivity analyses were per-
formed. First, we verified if our estimates were affected
by the adopted criteria for defining UGIC. Data were
analysed according to alternative diagnostic criteria, i.e.
those recently proposed by Cadarette et al. while investi-
gating oral BPs safety [28], as well as those used by a
collaborative project aimed to exploit European health-
care databases for drug safety signal detection, the so
called EU-ADR Project [35]. Second, we verified if our
estimates were affected by the adopted criteria for defining
exposure. With this aim we used time-window lengths of
7, 15 or 45 days prior the index date for defining current
use, alternative to 30 days as in the main analysis.
The SAS statistical package was used for the analyses
(SAS, Version 9.1; SAS Institute, Cary, North Carolina,
USA). For all hypotheses tested two-tailed p-values less
than 0.05 were considered to be significant.
Ethical considerations
The study protocol was notified to the Italian Medicines
Agency (AIFA) and to the local ethics committees of all
the territorial units involved in the investigation. There
was no legal requirement for ethics committee approval
since we used only unidentifiable patient data and did not
contact the patients.
Results
Sample selection
The distribution of the exclusion criteria is shown in
Figure 1. At entry, the 68,970 patients who were included
into the cohort had mean age of 76.2 years (SD 12.5 years)
and 71% of them were women. During follow-up these
patients accumulated 220,135 person-years of observation
and generated 804 hospital admissions for UGIC, with an
incidence rate of 36.5 cases per 10,000 person-years. The
804 patients who experienced hospitalization for UGIC
(case patients) were matched to 12,787 controls.
Patients
At the cohort entry, mean age of cases and controls was
79.9 years (SD: 9.9 years), and nearly 72% of them were
women (matching variables). As shown in Table 1, there
was not statistical evidence that case patients and con-
trols differed for use to BPs during the entire observa-
tional period, as well as during current and past periods.
Similarly, there was not evidence that cases and controls
differ for BPs type and regimen refilled during the current
period. Conversely, with the exception of statins and cal-
cium channel blockers, co-treatments with the other con-
sidered drugs, as well as the presence of at least one sign of
Patients with less than 60 days of follow-up
(138)
Patients who previously took BPs
(6,333)
Patients aged 45 years or older, discharged 
between July 1, 2003 and December 31, 2005 
with a diagnosis of osteoporotic bone fractures
(84,558) Patients previously discharged for 
osteoporotic fractures , gastrointestinal 
problems or other disease
(9,117)
Patient discharged for new osteoporotic bone 
fractures
(75,441)
Patients starting BPs therapy for secondary 
prevention of osteoporotic fractures 
(69,108)
Patients starting BPs therapy for secondary 
prevention of osteoporotic fractures with more 
than 60 days of follow-up
(68,970)
Patients who experienced  
incident hospitalization for 
UGIC until December 31, 
2007
804 case patients
12,787 matched controls
Pa
tie
nt
 w
ith
 e
xc
lu
si
on
 c
ri
te
ri
a
Figure 1 Study flow diagram. AIFA-BEST Project, Italy, 2003–2007. Flow chart of inclusion and exclusion criteria. BPs: Bisphosphonates.
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than controls.
Use of bisphosphonates and the risk of upper
gastrointestinal complications
Compared with non users, patients who used BPs any-
time during the entire observational period, as well as
those who were exposed during current or past period,
did not show significant risk excess of UGIC (Figure 2).
In addition, there was no evidence that UGIC risk was
heterogeneous across the categories of both types and
regimens of BPs refilled anytime during the observa-
tional period, nor during current and past periods.
As shown in Figure 3, there was not statistical evi-
dence that the UGIC risk associated with current use of
BPs was heterogeneous across the categories of patients
stratified according with co-treatments and comorbidity.
It should be observed, however, that large confidence in-
tervals were obtained for some strata. This was due to
the few patients who concomitantly used BPs and other
medicaments such as corticosteroids, statins or calcium
channel blockers (being the corresponding prevalence
8.6%, 9.3% and 13.3% respectively).
Sensitivity analyses
Figure 4 shows that the adjusted OR did not substan-
tially change by varying criteria for defining diagnosis of
UGIC (box A) nor the length of exposure time-window
for defining current use of BPs (box B).Discussion
In this large nested case–control study we did not found
evidence of increased severe UGIC risk associated with
current and/or past use of BPs in the setting of second-
ary prevention of osteoporotic fractures. We also found
that the type and regimen of BPs administered, as well
as the concurrent use of other drugs known for increas-
ing UGIC, did not modify the gastrointestinal safety of
BPs.
Comparison with literature
Our results are consistent with those of two randomized
clinical trials (RCTs), FIT (Fracture Intervention Trial)
and VERT (Vertebral Efficacy of Risedronate Therapy)
trials [16,36], both reporting similar gastrointestinal side-
effects profile in patients who received BPs and those
on placebo. Similarly to ours, a pooled analysis from
9 RCTs found that the rate of upper GI tract adverse
events was similar across risedronate and placebo groups,
and that concomitant use of aspirin, NSAIDs, H2-recep-
tor antagonists and/or proton pump inhibitors did not
lead to significant between-group differences in the UGIC
risk [37].
Validity of our main findings seems to have sup-
port by the observed association between use of other
medicaments known to cause GI complications and
the considered outcome. For example, consistently
with literature, we found that, with respect to con-
trols, case patients had higher prevalence in the use of
Table 1 Selected tracts of the 804 cases of upper gastrointestinal complications and 12,787 controls
Case patients Controls p-value*
BPs exposure†
No use 709 (88.2%) 11,345 (88.7%) 0.6029
Current use 38 (4.7%) 643 (5.0%)
Past use 57 (7.1%) 799 (6.2%)
Type prescribed during the current period
Alendronate 30 (79.0%) 412 (64.1%) 0.0620
Risedronate 8 (21.0%) 231 (35.9%)
Regimen prescribed during the current period
Weekly 37 (97.4%) 631 (98.1%) 0.7376
Daily 1 (2.6%) 12 (1.9%)
Use of other medicaments‡
Antidepressants 139 (17.3%) 1,841 (14.4%) 0.0242
Antithrombotic 240 (29.9%) 3,174 (24.8%) 0.0014
Gastroprotective agents 211 (26.2%) 1,993 (15.6%) <0.0001
Corticosteroids 65 (8.1%) 533 (4.2%) <0.0001
Statins 41 (5.1%) 724 (5.7%) 0.5021
Calcium channel blockers 105 (13.1%) 1,548 (12.1%) 0.4223
Other antihypertensive drugs 371 (46.1%) 5,294 (41.4%) 0.0082
Nonsteroidal antiinflammatory drugs 170 (21.1%) 1,529 (12.0%) <0.0001
Co-morbidity#
0 629 (78.2%) 11,531 (90.2%) <0.0001
≥1 175 (21.8%) 1,256 (9.8%)
BPs: Bisphosphonates.
†A patient was defined current user if at least one prescription of BPs was refilled within 30 days or less prior the index date. A patient was defined past user if at
least one prescription of BPs was refilled later than 31 days prior the index date. No users were patients who during the entire observational period did not
experience BPs dispensation.
‡Measured over the 60-day period prior the index date.
#Charlson comorbidity index score measured in the six months prior the entry into the cohort and during the entire observational period.
*According to chi-square test.
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class of antihypertensive agents, and NSAIDs, in the
presence of chronic comorbidities [38-45]. Conversely
to others, we did not confirm that recent use of calcium-
channel blockers and statins increased the risk of
UGIC [45,46].
We found that cases had higher use of gastropro-
tective drugs than controls. As we cannot suppose that
gastroprotective agents cause GI complications, the
more likely explanation is that physicians more likely
prescribe gastroprotective agents to those patients with
a history of GI complications, or to those at whom GI
symptoms sudden occurred, i.e. to patients at higher
UGIC risk [47].
Strengths and limitations
Several peculiar features of our study deserve to be men-
tioned. First, the study is based on data from a very large
unselected population, which was made possible bythe fact that in Italy a cost-free uniformly organized
healthcare system involves practically all citizens. By
drawing out healthcare utilization data from nearly 30%
of the whole Italian population, we were able to build
one of the largest observational studies performed on
the GI safety of bisphosphonates in the setting of sec-
ondary prevention of osteoporotic fractures. Accord-
ingly with the included number of cases and controls,
as well as of the observed number of controls who cur-
rently used BPs, even small gastrointestinal effects associ-
ated with current use of BPs (ORs ≥ 1.5) could have been
detected from our study as significant (with p < 0.05 and
power of 80%). Our data, furthermore, reflecting routine
clinical practice, are unaffected by selective participation
and recall bias.
Second, the drug prescription database provided highly
accurate data, because report of prescriptions by the
pharmacies is essential for reimbursement and filling
of an incorrect report about the dispensed drugs has
OR (95% CI) p-value
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Figure 2 Adjusted odds ratios (and 95% confidence intervals) of upper gastrointestinal complications associated with anytime, current
and past exposure to bisphosphonates as a whole (all) as well as to type (alendronate and risedronate) and regimen (daily and weekly)
of the latest dispensed bisphosphonates. AIFA-BEST Project, Italy, 2003–2007. Odds ratios estimated with conditional logistic regression model.
Estimates concerning main analysis (all) were adjusted for use of other medicaments in the 60-day period and for the Charlson index measured
before the index date. Estimates concerning subgroup analysis were obtained by including the interaction terms combining the effect of anytime,
current or past exposure to BPs together with type and regimen of the dispensed BPs. P-values concern comparison of BPs
effect across patient subgroups. BPs: Bisphosphonates.
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analyses allowed us to verify the robustness of our find-
ings. For example, we found that the criteria employed
for UGIC diagnosis, as well as for defining current BPs
use, did not substantially affect our estimates. This fur-
ther strengthens the evidence that the use of BPs un-
likely causes serious GI complications.
Our study has a number of potential limitations. First,
as outcomes were drawn from hospitalized patients, our
data only concern severe GI complications requiring
hospitalization. Second, because of privacy regulations,
hospital records were not available for analysis so diag-
noses cannot be scrutinized and validated. Third, mis-
classification of BPs exposure might occur because, once
the drug is dispensed, it is possible that patients did not
assume it. If this happens when GI symptoms occur, a
protopathic bias is introduced dragging the investigated
association towards that expected under the null hy-
pothesis [49].
Fourth, besides the very large sample size, some of
our findings are likely to be affected by random uncer-
tainty. For example, during the study period BPs were
rarely dispensed once-daily, so the lack of evidence ofdifferential effect of BPs according to the dispensation
regimen is particularly weak. Similarly, the lack of evi-
dence of a synergistic effect between BPs and other
known GI-harmful drugs might be due to the few num-
ber of patients taking co-therapies during the current
period.
The uncommon dispensation of BPs and other medi-
caments observed in our setting, however, has important
clinical implications. For example, patients with more
severe form of osteoporosis may need to assume antiin-
flammatory agents (e.g. NSAIDs or corticosteroids) for
the symptomatic relief of pain secondary to this disease.
In this way, a high prevalence of patients who concomi-
tantly use BPs and antiinflammatory agents are expected
in routine clinical practice. Since BPs co-therapy with
NSAIDs has been found to increase the risk of peptic
ulcer in rheumatoid arthritis patients with long-term
NSAIDs treatment [30], this practice should be avoided,
as often occurs in our setting.
Finally, as in all observational studies, there is always
some concern for residual confounding due to unmeas-
ured factors. For example, under the assumption that
use of BPs increases the UGIC risk, over-the-counter
OR (95% CI) p-value
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Antithrombotics
Gastroprotective
agents
Cosrticosteroids
NSAIDs
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Figure 3 Combined action of current exposure to bisphosphonates, concurrent exposure to other medicaments and categories of
Charlson comorbidity index on the risk of upper gastrointestinal complications. AIFA-BEST Project, Italy, 2003–2007. Odds ratios estimated
with conditional logistic regression model. Estimates were obtained by including the interaction terms combining the effect of current exposure
to BPs together with concurrent use of other medicaments and the categories of the Charlson index. P-values concern comparison of BPs effect
across patient subgroups. BPs: Bisphosphonates.
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once GI symptoms occur. On the other hand, the as-
sumption of over-the-counter antiinflammatory agents
might be reduced when GI symptoms occur. Both
these sources of selective exposures would drag the
investigated association towards that expected under
the null hypothesis.A. Diagnostic criteria for UGIC
B. Length of current exposure
Cadarette’s Criteria
EU-ADR Criteria
0.4 0.6 0.8 1
7 days
15 days
45 days
Figure 4 Influences of diagnostic criteria for defining upper gastroint
for defining current use of BPs (panel B) on the observed odds ratio
exposure to bisphosphonates. AIFA-BEST Project, Italy, 2003–2007. Odds
were adjusted for use of medicaments in the 60-day period and for the Ch
criteria are reported in Additional file 1. BPs: Bisphosphonate.Conclusions
In summary this study provides further evidence that BPs
dispensed for secondary prevention of osteoporotic frac-
tures are not associated with increased risk of severe gastro-
intestinal complications. Further research is required to
clarify the role of co-medication with BPs and other medi-
caments in inducing upper gastrointestinal complications.0.87 (0.63-1.17)
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OR  (95% CI)
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estinal complications (panel A), and of the time-window length
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ratios estimated with conditional logistic regression model. Estimates
arlson index measured before the index date. Details for diagnostic
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Additional file 1: Drugs and diagnoses codes used for the study
purpose [28,35].
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